Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

Recent & Breaking News (CSE:AGN)

The StockTalk Cannabis Report: June 25, 2021

Dave Jackson June 25, 2021

Algernon Pharmaceuticals (CSE:AGN) targets first human study of its psychedelic drug DMT for Q4, 2021

John Ballem  June 17, 2021

Algernon Pharmaceuticals Targets First Human Study of its Psychedelic Drug DMT Stroke Program for Q4, 2021

GlobeNewswire June 17, 2021

Algernon Pharmaceuticals Launches Pancreatic Cancer Clinical Research Program with Ifenprodil

GlobeNewswire June 3, 2021

Algernon Pharmaceuticals Shares an Animal Study that Confirms the Effectiveness of DMT in Treating Stroke

John Ballem  May 28, 2021

Algernon Pharmaceuticals Highlights New Animal Study Showing Effectiveness of Psychedelic Drug DMT in Treatment of Stroke

GlobeNewswire May 27, 2021

Algernon Pharmaceuticals (CSE:AGN) receives positive feedback from U.S. FDA for its DMT clinical research program

John Ballem  May 17, 2021

Algernon Pharmaceuticals Receives Positive Feedback from U.S. FDA for Psychedelic Drug DMT Clinical Research Program for Stroke

GlobeNewswire May 17, 2021

Algernon Pharmaceuticals Inc. Announces Ifenprodil Reduced Interleukin 6 in Phase 2b/3 COVID Study

John Ballem  May 12, 2021

Algernon Pharmaceuticals Announces Ifenprodil Reduced Interleukin 6 in Phase 2b/3 COVID Study

GlobeNewswire May 12, 2021

Algernon Pharmaceuticals Announces 50% Enrollment of its Ifenprodil IPF and Chronic Cough Phase 2 Human Study

GlobeNewswire May 11, 2021

Algernon Pharmaceuticals (CSE:AGN) files end of Phase 2 meeting request with U.S. FDA

Brieanna McCutcheon  April 26, 2021

Algernon Pharmaceuticals Files End of Phase 2 Meeting Request with U.S. FDA for its COVID-19 Trial of Ifenprodil

GlobeNewswire April 26, 2021

Algernon Pharmaceuticals (CSE:AGN) to file End-of-Phase 2 meeting request with U.S. FDA

Brieanna McCutcheon  April 8, 2021

Algernon Working to Meet with FDA on Possible Phase 3 COVID-19 Trial

Stockhouse Editorial April 8, 2021

Algernon Pharmaceuticals to File End-of-Phase 2 Meeting Request with U.S. FDA for Possible Ifenprodil Phase 3 COVID-19 Trial

GlobeNewswire April 8, 2021

Algernon Pharmaceuticals Announces Appointment of Global Expert Dr. Steven L. Wolf for DMT Stroke Program

GlobeNewswire April 6, 2021

Algernon Pharmaceuticals (CSE:AGN) reports on latest phase of its Ifenprodil COVID-19 trial

Trevor Abes  March 31, 2021

Algernon Pharmaceuticals Announces Topline Data From its Phase 2b/3 COVID-19 Trial of Ifenprodil

GlobeNewswire March 31, 2021

Algernon Joins the First Psychedelic Stock Index ETF on the Market

Stockhouse Editorial March 29, 2021